DeepLook Medical’s flagship product, DL Precise™, is an AI-powered software that uses shape-recognition algorithms to visualize, measure, and segment abnormal growths in dense breast tissue. The company positions DL Precise™ as a tool to improve accuracy in detecting and assessing suspicious lesions, with the potential to enhance early cancer detection and patient outcomes. DeepLook says its technology is the first in a series of products built on its unique shape-recognition software and leveraged alongside complementary AI advances and patented technology. The company plans to use newly raised capital to further commercialize its technology with current and new partners, explore applications in additional imaging modalities, and broaden its global presence. DeepLook emphasizes improving physician diagnosis and treatment decisions across oncology through clearer tumor morphology delineation. The press release highlights Xcellerant’s support and strategic involvement as part of its commercialization efforts. DeepLook Medical, led by CEO Marissa Fayer and based in New Haven, Connecticut, develops AI software to improve visualization of suspicious masses in dense breasts. Its flagship product, DL Precise, is an FDA-cleared shape-recognition platform that overlays onto existing imaging screens to provide one-click measurement, segmentation, and visualization. DL Precise delineates tumor morphology using a single-click deterministic algorithm and is compatible with mammography, ultrasound, CT, and MRI. The product has entered the commercial market through partnerships with Barco, Blackford, Tempus, and Radical Imaging. DeepLook plans to use the $1.7M funding to hire talent, advance next-generation products, expand sales and partnerships, support additional clinical research and publications, and extend global IP and regulatory protections and clearances. The company is also leveraging complementary AI advances to enhance the reach and impact of its patented technology.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2024